Sibnayal® (potassium citrate/potassium bicarbonate) has been launched on March 1, 2023Reference price equals to an annual treatment cost of €15,000 per patient.PARIS--(BUSINESS WIRE)--Regulatory News:Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the developme...
Sibnayal (potassium citrate/potassium bicarbonate) has been launched on March 1, 2023 Reference price equals to an annual treatment cost of €15,000 per patient. Regulatory News: Advicenne
Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”), a specialty pharmaceutical company offering end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators, announced today that it has signed an exclusive distribution agreement with Paris-based specialty ...
Advicenne agreement further validates Avanzanite's unique business model and establishes it as the go-to commercialization partner for medicines treating rare diseases across Europe Avanzanite
Advicenne agreement further validates Avanzanite’s unique business model and establishes it as the go-to commercialization partner for medicines treating rare diseases across EuropeAvanzanite now transitioning to sales execution with the first anticipated commercial launch in Germany mid 2023 AMSTERDAM--(...
Sibnayal® will now be available in four of the five major European markets Significant expansion of commercial opportunities for Sibnayal® (potassium citrate/ potassium bicarbonate) Regulatory
Significant progress in the operational deployment of partnerships to support Sibnayal® commercial roll-out Sustained growth in the number of patients with access to Sibnayal® in Europe Regulatory
Significant progress in the operational deployment of partnerships to support Sibnayal® commercial roll-out Sustained growth in the number of patients with access to Sibnayal® in Europe Regulatory
Significant progress in the operational deployment of partnerships to support Sibnayal® commercial roll-outSustained growth in the number of patients with access to Sibnayal® in EuropePARIS--(BUSINESS WIRE)--Regulatory News:This replaces the announcement made at 5:45 PM CET on February 1st 2023 due to the following...
Sales of Sibnayal® reached 1.4 million euros, a significant increase of 40% over one year Significant growth acceleration in H2 2022 Regulatory News: Advicenne (Euronext: ADVIC), a specialty